trospium
Selected indexed studies
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. (JAMA Psychiatry, 2024) [PMID:38691387]
- Trospium. (, 2012) [PMID:31644086]
- Xanomeline/Trospium Chloride: First Approval. (Drugs, 2025) [PMID:39715912]
_Worker-drafted node — pending editorial review._
Connections
trospium is a side effect of
Sources
- Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. (2024) pubmed
- Trospium. (2012) pubmed
- Xanomeline/Trospium Chloride: First Approval. (2025) pubmed
- Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. (2024) pubmed
- Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. (2024) pubmed
- Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. (2025) pubmed
- Xanomeline-trospium (Cobenfy(TM)) for Schizophrenia: A Review of the Literature. (2025) pubmed
- Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. (2024) pubmed
- Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia. (2023) pubmed
- Xanomeline and Trospium. (2006) pubmed